GSK四价灭活流感疫苗在比利时、德国和西班牙2022/2023季节的安全性增强监测
本研究在比利时、德国和西班牙开展2022/2023流感季安全性增强监测,1332名接种GSK四价灭活流感疫苗者(含43名儿童)中97.8%返回不良反应卡。接种后7天内未报告与疫苗相关的严重不良事件,支持该疫苗在所有推荐年龄组中具有可接受的安全性。
要点
- 接种后7天内未报告与GSK四价灭活流感疫苗相关的严重不良事件。
- 第1剂后49.8%报告至少1例不良事件,最常见为注射部位疼痛(37.6%)。
- 成人18-65岁不良事件报告率最高(59.7%),6-35月龄最低(23.5%)。
核心结论
- 在所有年龄和严重疾病风险组中,接种后7天内未报告与GSK四价灭活流感疫苗相关的严重不良事件。
- 研究支持并确认GSK四价灭活流感疫苗在所有推荐年龄组中具有可接受的安全性。
研究设计与样本
- 这是一项在比利时、德国和西班牙开展的增强安全性监测研究。
- 共1332名参与者(53.6%为女性)至少接种1剂GSK四价灭活流感疫苗,其中43名儿童接种2剂。
- 接种者及儿童父母/监护人或法定代表被邀请填写不良反应卡,报告接种后7天内不良事件。
主要发现
- 97.8%的不良反应卡被完成并返回。
- 第1剂后所有年龄组中49.8%的参与者报告至少1例不良事件。
- 第1剂后累计频率>5%的不良事件包括注射部位疼痛(37.6%)、疲劳(15.0%)、头痛(13.2%)、注射部位肿胀(9.3%)、肌痛(7.6%)和注射部位红斑(7.4%)。
- 第1剂后不良事件报告率:18-65岁成人59.7%,3-17岁47.0%,>65岁35.7%,6-35月龄23.5%。
- 第2剂后18.6%的参与者报告至少1例不良事件,全身性疾病和给药部位条件仍为最常见。
临床怎么用
- 临床药师可参考本监测结果,向接种者说明接种后7天内常见不良事件以注射部位反应和全身轻度反应为主。
- 对于儿童和成人接种者,可告知严重不良事件未报告,安全性可接受。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Seasonal influenza is prevented through annual vaccination, especially in children and older adults. These vaccines are annually updated based on World Health Organization recommendations and require continuous safety monitoring. OBJECTIVE: We assessed the frequency and severity of adverse events within 7 days of administering GSK's inactivated quadrivalent seasonal influenza vaccine (IIV4) in Belgium, Germany, and Spain during the 2022/2023 influenza season. METHODS: In this enhanced safety surveillance study, adults who received GSK's IIV4 and parents/guardians/legally acceptable representatives of vaccinated children (aged 6 months-17 years) were invited to complete adverse drug reaction cards reporting adverse events within 7 days post-vaccination. RESULTS: In total, 1332 participants (53.6% female) received at least one dose of GSK's IIV4, including 43 children who received two doses. Overall, 97.8% of adverse drug reaction cards were completed and returned in the study. All participants in Belgium were adults, while 54.7% and 7.4% in Spain and Germany, respectively, were pediatric participants aged 6 months-17 years. After Dose 1, across all age groups, 49.8% of participants reported at least one adverse event. The most common adverse events (cumulative frequency >5%) following Dose 1 were injection-site pain (37.6%), fatigue (15.0%), headache (13.2%), injection-site swelling (9.3%), myalgia (7.6%), and injection-site erythema (7.4%). Across all countries, adverse events were most common in adults aged 18-65 years (59.7%), followed by those aged 3-17 years (47.0%), >65 years (35.7%), and 6-35 months (23.5%). After Dose 2, 18.6% of participants reported at least one adverse event, with general disorders and administration site conditions again being the most frequent. CONCLUSIONS: Across all age and risk groups for serious disease, no serious adverse events related to GSK's IIV4 were reported within 7 days post-vaccination. This study supports and confirms the acceptable safety profile of GSK's IIV4 across all recommended age groups. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov number: not applicable.
引用
- de la Cueva IS, Gerber JE, Hastie A, et al. Enhanced Safety Surveillance of GSK's Inactivated Quadrivalent Seasonal Influenza Vaccine in Belgium, Germany, and Spain During the 2022/2023 Influenza Season. Drug Saf. 2024. PMID: 38949714. doi:10.1007/s40264-024-01456-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。